Ligand Pharma (LGND) Tops Q3 EPS by 6c, Offers FY20 and FY21 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. TSCO
9. BE
10. SLM

Go back to Ligand Pharma (LGND) Tops Q3 EPS by 6c, Offers FY20 and FY21 Guidance

Ligand Reports Third Quarter 2020 Financial Results

October 30, 2020 8:00 AM EDT

Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.

"Our business is performing very well across the board. We are pleased to be reporting strong third quarter financial results and foresee substantial... More